Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- anistreplase
- Uro-Pain Dual Action (methenamine / sodium salicylate)
Interactions between your drugs
anistreplase sodium salicylate
Applies to: anistreplase, Uro-Pain Dual Action (methenamine / sodium salicylate)
MONITOR CLOSELY: Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.
MANAGEMENT: Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment. Local guidelines and prescribing information for individual thrombolytic drugs should be consulted for further recommendations.
References (8)
- (2001) "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc
- (2001) "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical
- (2001) "Product Information. Activase (alteplase)." Genentech
- (2001) "Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Retavase (reteplase)." Boehringer Mannheim
- (2001) "Product Information. TNKase (tenecteplase)." Genentech
- Harder S, Klinkhardt U (2000) "Thrombolytics: drug interactions of clinical significance." Drug Saf, 23, p. 391-9
- Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians (2001) "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest, 119(1 Suppl), 1S-2S
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Plavix
Plavix (clopidogrel) is used to prevent blood clots after a recent heart attack or stroke. Includes ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Coumadin
Coumadin is used to prevent heart attacks, strokes, and blood clots in veins and arteries. Learn ...
Brilinta
Brilinta (ticagrelor) is used to lower your risk of having a stroke or serious heart problems after ...
Toprol-XL
Toprol-XL (metoprolol) is a beta-blocker used to treat angina and high blood pressure. Includes ...
Lopressor
Lopressor is used for angina, angina pectoris prophylaxis, heart attack, high blood pressure
Tenormin
Tenormin is a beta-blocker used to treat angina and high blood pressure. Includes Tenormin side ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.